<SEC-DOCUMENT>0001513162-20-000073.txt : 20200406
<SEC-HEADER>0001513162-20-000073.hdr.sgml : 20200406
<ACCEPTANCE-DATETIME>20200406143017
ACCESSION NUMBER:		0001513162-20-000073
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200401
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200406
DATE AS OF CHANGE:		20200406

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	DENTAL EQUIPMENT & SUPPLIES [3843]
		IRS NUMBER:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37863
		FILM NUMBER:		20776733

	BUSINESS ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		9496452111

	MAIL ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<head><title>Form 8-K</title> </head> <body vlink=#954f72 link=#0563c1 lang=EN-US> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center><b><font style="FONT-SIZE:14pt; LINE-HEIGHT:174%">UNITED STATES<a name=Form_8_K></font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center><b><font style="FONT-SIZE:14pt; LINE-HEIGHT:174%">SECURITIES AND EXCHANGE COMMISSION</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center><b><font style="FONT-SIZE:12pt; LINE-HEIGHT:174%">WASHINGTON, DC 20549</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center><font style="FONT-SIZE:12pt; LINE-HEIGHT:174%">_______________</font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:12pt 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center><b><font style="FONT-SIZE:16pt; LINE-HEIGHT:174%">FORM 8-K</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:12pt 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center><b><font style="FONT-SIZE:12pt; LINE-HEIGHT:174%">CURRENT REPORT</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; page:WordSection1' align=center><b><font style=FONT-SIZE:12pt>Pursuant to Section 13 or 15(d) of the</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center><b><font style="FONT-SIZE:12pt; LINE-HEIGHT:174%">Securities Exchange Act of 1934</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:6pt 0in 0pt; page:WordSection1' align=center><font style=FONT-SIZE:11pt>Date of Report (Date of earliest event reported):<b>&nbsp; April 1, 2020</b></font></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:12pt 0in 0pt; page:WordSection1' align=center><b><font style=FONT-SIZE:20pt>BIOMERICA, INC.</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 12pt; page:WordSection1' align=center>(Exact name of registrant as specified in its charter)</p> <div style=page:WordSection1 align=center> <table width=696 bordercolor=transparent style=BORDER-COLLAPSE:collapse cellpadding=0 cellspacing=0> <tr style=HEIGHT:13pt> <td width=232 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:174pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt"> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><font style=COLOR:black>Delaware</font></b></p></td> <td width=232 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:174pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt"> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><font style=COLOR:black>001-37863</font></b></p></td> <td width=232 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:174pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt"> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><font style=COLOR:black>95-2645573</font></b></p></td></tr> <tr style=HEIGHT:26pt> <td width=232 style="HEIGHT:26pt; WIDTH:174pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>(State or Other Jurisdiction</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>of Incorporation)</p></td> <td width=232 style="HEIGHT:26pt; WIDTH:174pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>(Commission</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>File Number)</p></td> <td width=232 style="HEIGHT:26pt; WIDTH:174pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>(IRS Employer</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center>Identification No.)</p></td></tr></table></div> <div style=page:WordSection1 align=center>&nbsp;</div> <div style=page:WordSection1 align=center> <table width=696 bordercolor=transparent style=BORDER-COLLAPSE:collapse cellpadding=0 cellspacing=0> <tr style=HEIGHT:13pt> <td width=89 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:67pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in'>&nbsp;</p></td> <td width=517 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:388pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><font style=COLOR:black>17571 Von Karman Ave. Irvine, California</font></b></p></td> <td width=89 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:67pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><font style=COLOR:black>92614</font></b></p></td></tr> <tr style=HEIGHT:14pt> <td width=89 style="HEIGHT:14pt; WIDTH:67pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:2pt 0in'>&nbsp;</p></td> <td width=517 style="HEIGHT:14pt; WIDTH:388pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt"> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style=COLOR:black>(Address of Principal Executive Offices)</font></p></td> <td width=89 style="HEIGHT:14pt; WIDTH:67pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt"> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style=COLOR:black>(Zip Code)</font></p></td></tr></table></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:12pt 0in 0pt; page:WordSection1' align=center>Registrant's telephone number, including area code:&nbsp; <b>(949) 645-2111</b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:12pt 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center><b><font style=COLOR:black>Not Applicable</font></b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:174%; page:WordSection1' align=center>(Former name or former address if changed since last report)</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; page:WordSection1'>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:12pt 0in 0pt; page:WordSection1'><font size=2 style=FONT-SIZE:12pt face=Wingdings>&#168;</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; page:WordSection1'><font size=2 style=FONT-SIZE:12pt face=Wingdings>&#168;</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; page:WordSection1'><font size=2 style=FONT-SIZE:12pt face=Wingdings>&#168;</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; page:WordSection1'><font size=2 style=FONT-SIZE:12pt face=Wingdings>&#168;</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:3pt 0in 0pt; LINE-HEIGHT:120%; page:WordSection1'>Securities registered pursuant to Section 12(b) of the Act:</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; page:WordSection1'>&nbsp;</p> <div style=page:WordSection1 align=center> <table width=683 bordercolor=transparent style=BORDER-COLLAPSE:collapse cellpadding=0 cellspacing=0> <tr style=HEIGHT:14pt> <td width=235 style="HEIGHT:14pt; WIDTH:176pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black">Title of each class</font></u></b></p></td> <td width=92 style="HEIGHT:14pt; WIDTH:69pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black">Trading Symbol</font></u></b></p></td> <td width=356 style="HEIGHT:14pt; WIDTH:267pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black">Name of each exchange on which registered</font></u></b></p></td></tr> <tr style=HEIGHT:14pt> <td width=235 style="HEIGHT:14pt; WIDTH:176pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style="FONT-SIZE:9pt; COLOR:black">Common Stock, par value $0.08</font></p></td> <td width=92 style="HEIGHT:14pt; WIDTH:69pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style="FONT-SIZE:9pt; COLOR:black">BMRA</font></p></td> <td width=356 style="HEIGHT:14pt; WIDTH:267pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:2pt 0in' align=center><font style="FONT-SIZE:9pt; COLOR:black">NASDAQ Capital Market</font></p></td></tr></table></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; page:WordSection1' align=left>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&nbsp;&nbsp; Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font style=FONT-FAMILY:Wingdings>&#168;</font> </p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; page:WordSection1'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; page:WordSection1' align=left>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp; <font style=FONT-FAMILY:Wingdings>&#168;</font></p><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%'><br clear=all></font> <div style=page:WordSection2> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 12pt' align=center>1<b> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> <p /></b> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 12pt'><b>Item 1.01 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Entry into a Material Definitive Agreement</b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0.5in' align=justify>On April 1, 2020, Biomerica, Inc. (&#147;Biomerica&#148;) entered into two separate non-exclusive license agreements (the &#147;License Agreements&#148;) with the Mount Sinai Icahn School of Medicine in New York (&#147;Mount Sinai&#148;) to license technology from Mount Sinai that Biomerica intends to use to scale up and manufacture a laboratory version serological test for SARS-CoV-2 coronavirus.&nbsp; This test uses the ELISA microplate format that can run on existing open system equipment found in most hospitals and clinical laboratories in the United States.&nbsp; The non-exclusive License Agreements provide for royalty payments to Mount Sinai based on a percentage of gross sales of commercial products manufactured and sold by Biomerica that incorporate the Mount Sinai technology licensed under the License Agreements. </p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt' align=justify>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0.5in' align=justify>While Biomerica believes it will be able to utilize the licensed technology to make and sell a commercial product, there can be no assurance Biomerica will be successful at transferring the technology, further developing the technology as needed for commercialization, incorporating the technology into its products, utilizing the technology for Biomerica&#146;s intended purposes, or manufacturing a final product that meets market demands or regulatory requirements.&nbsp; Biomerica intends to apply for expedited clearance with the FDA under the new Emergency Use Authorization process for this new test format.</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0.5in'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b>Forward-Looking Statements</b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0.5in' align=justify>The Private Securities Litigation Reform Act of 1995 provides a &#147;safe harbor&#148; for forward-looking statements. Certain information included in this Current Report on Form 8-K contains statements that are forward-looking, such as statements relating to Biomerica&#146;s expectations of the use of the technology licensed from Mount Sinai, Biomerica&#146;s commercialization and scaling of its SARS-CoV-2 serological tests, and payments to be made to Mount Sinai related to the License Agreements.&nbsp; Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: Biomerica&#146;s ability to transfer, further develop, integrate and use the licensed technology; Biomerica&#146;s ability to manufacture and scale its commercial products using the licensed technology; results of studies testing the efficacy of Biomerica&#146;s commercial products; regulatory approvals necessary prior to commercialization of Biomerica&#146;s products; availability of Biomerica&#146;s products; capacity, resource and other constraints on Biomerica&#146;s suppliers; dependence on third party supply chain and manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for Biomerica&#146;s commercial products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations; and Biomerica&#146;s ability to obtain patent protection and other intellectual property protections on any aspects of its test technologies or commercial products; and Biomerica&#146;s ability to develop and manufacture certain tests it has not yet finalized and has never previously manufactured.&nbsp; &nbsp;Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in Biomerica&#146;s operating results due to its business model and expansion plans, downturns in international and or national economies, Biomerica&#146;s ability to raise additional capital, the competitive environment in which Biomerica will be competing, and Biomerica&#146;s dependence on strategic relationships.&nbsp; Additional risks and uncertainties associated with market conditions and Biomerica are discussed in Biomerica&#146;s filings with the Securities and Exchange Commission, including the &#147;Risk Factors&#148; section of Biomerica&#146;s Annual Report on Form 10-K for the year ended May 31, 2019. Biomerica is under no obligation to update any forward-looking statements after the date of this Form 8-K.</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt' align=justify>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><b>Item 7.01 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Regulation FD Disclosure</b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0.5in'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0.5in' align=justify>On April 2, 2020, Biomerica issued a press release announcing the execution of the two License Agreements. A copy of Biomerica&#146;s press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 in its entirety. Both of the License Agreements are non-exclusive and Mount Sinai is making this technology available to other licensees.</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:47.05pt' align=justify>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; TEXT-INDENT:0.5in' align=justify>The information contained in, or incorporated into, this Item 7.01 is being furnished and shall not be deemed &#147;filed&#148; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the&nbsp;Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference to such filing.</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; MARGIN:0in 0in 0pt'><b><font style=COLOR:black>Item&nbsp;9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements and Exhibits</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt 0.5in; TEXT-INDENT:-0.25in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 12pt 0.5in; TEXT-INDENT:-0.25in'><font style=FONT-SIZE:10pt>(d) &nbsp; Exhibits. </font></p> <div align=center> <table width=99% bordercolor=transparent style="WIDTH:99.42%; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr> <td width=9% nowrap style="WIDTH:9.26%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%' align=center><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%">&nbsp;</font><b><u><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%">Number</font></u></b></p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%">&nbsp;&nbsp;</font></p></td> <td width=89% nowrap style="WIDTH:89.66%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0.7pt; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'><b><u><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%">Description</font></u></b></p></td></tr> <tr> <td width=9% style="WIDTH:9.26%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=89% style="WIDTH:89.66%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td></tr> <tr> <td width=9% style="WIDTH:9.26%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%' align=center>99.1</p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=89% style="WIDTH:89.66%; PADDING-BOTTOM:0in; PADDING-TOP:0.7pt; PADDING-LEFT:0in; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:115%'>Press Release issued April 2, 2020.</p></td></tr></table></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:11.25pt 0in 0pt; LINE-HEIGHT:120%' align=center>2<b> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </p> </b> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:11.25pt 0in 0pt; LINE-HEIGHT:120%' align=center><b>SIGNATURE</b></p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:7.5pt 0in 0pt; LINE-HEIGHT:120%; TEXT-INDENT:23pt'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 7pt 275pt; TEXT-INDENT:-23pt'>&nbsp;</p> <div align=center> <table width=600 bordercolor=transparent style="WIDTH:6.25in; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><a name=T13></p></a></td> <td width=47% colspan=2 nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black"><b>BIOMERICA, INC.</b></font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> </tr><tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><a name=T13><font style="FONT-SIZE:11pt; COLOR:black">Date:&nbsp; April 3, 2020</font></a></p></td> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">By:</font></p></td> <td width=47% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:47%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">&nbsp;/s/&nbsp;Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Chief Executive Officer</font></p></td></tr></table></div> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>3</p></div></a></body>
<!-- EDGAR Validation Code: 5ECF39B7 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<head> <title> Exhibit 99.1 </title> </head> <body vlink=#954f72 link=#0071bb lang=EN-US> <div style=page:WordSection1> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 12pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:11.5pt; FONT-FAMILY:"Open Sans"; COLOR:#0067b1'><img width=236 height=34 style="HEIGHT:38px; WIDTH:237px" src=image1.jpg></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 6pt; LINE-HEIGHT:normal'><b><font style="FONT-SIZE:17.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Biomerica Signs Two Definitive Agreements with Mount Sinai Medical School in New York to Scale-up a Laboratory Version Serological Test for COVID-19 That Enables High-Volume Screenings in Labs</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:6pt 0in 0pt; LINE-HEIGHT:normal'><b><font style="FONT-SIZE:17.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">&nbsp;&nbsp;</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 6pt 0.5in; LINE-HEIGHT:normal; TEXT-INDENT:-0.25in'><font style="FONT-SIZE:13.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">-<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><b><font style="FONT-SIZE:13.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Price point of this high-volume laboratory version test is expected be as low as $10 per patient </font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 0.5in; LINE-HEIGHT:107%'><b></b>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 6pt 0.5in; LINE-HEIGHT:normal; TEXT-INDENT:-0.25in'><font style="FONT-SIZE:13.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">-<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><b><font style="FONT-SIZE:13.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Once developed and scaled-up, Biomerica&#146;s existing production capacity could allow for over 1,000,000 tests per month at its manufacturing facilities in Irvine, California </font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 8pt 0.5in; LINE-HEIGHT:107%'><b></b>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40" lang=ES>IRVINE, CA--(April 02, 2020) - Biomerica Inc. </font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">(NASDAQ: </font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir">BMRA</font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">) today announced it has signed two separate definitive license agreements with Mount Sinai&#146;s Icahn School of Medicine in New York to license technologies &nbsp;&nbsp;pertaining to a laboratory version serological test for SARS-CoV-2 (&#147;COVID-19&#148;) virus infection which have been developed at Mount Sinai.&nbsp; This test uses the ELISA microplate format that can run on existing open system equipment found in most hospitals and clinical laboratories in the United States. &nbsp;&nbsp;&nbsp;&nbsp;</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Biomerica has extensive serological test development, scale-up and manufacturing capabilities and expertise.&nbsp; &nbsp;Based on the data received from Mt. Sinai, the Company intends to scale-up commercial manufacturing of the Mt. Sinai licensed technology.&nbsp; &nbsp;Biomerica has the equipment and capacity to manufacture over 1,000,000 tests in the ELISA microplate format per month at its manufacturing facility in Irvine, California. &nbsp;While there are unknowns about the transfer and scale-up process, if successful the Company believes it could have commercial sales within weeks.&nbsp; Biomerica will file for expedited clearance with the FDA under the new EUA process for this new test format. </font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">This ELISA microplate format is a serology test that detects antibodies (proteins produced by the immune system in response to infections) in the blood of patients who have been infected with the Covid-19 virus causing the current pandemic.&nbsp; These antibodies show up in detectable quantities in approximately 8 days following infection, and remain detectable for as long as 3 months or more. Persons who have tested positive for the antibodies and are no longer infectious, can possibly be cleared to return to work as they have a lower likelihood of reinfection and/or spreading the virus. </font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Serology tests are a potentially powerful tool for identifying anyone who has been infected, whether they had symptoms or not. Antibodies to coronaviruses typically remain in humans for up to 90 days or more. Serological testing is important in identifying the total number of people who have been infected with Covid-19 and will allow for further studies that establish whether the immune response protects from future re-infection. Further, this type of testing could be particularly important for the immune surveillance of health care workers, first responders, government workers, and others whose infection risks could be heightened by working with COVID-19 infected individuals. </font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <hr> <DIV style="PAGE-BREAK-BEFORE: always">&nbsp;</DIV> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Zackary Irani, Chairman and Chief Executive Officer, stated, &#147;If person has already been infected with SARS-CoV-2, they &nbsp;develop antibodies through an immune response that should give them immunity.&nbsp; The entire Biomerica team is working tirelessly to make our low-cost tests available to the hundreds of requests we have received. &nbsp;</font>&nbsp;<font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">At the same time, we still remaining committed to our strategy of growing our colorectal disease detection product EZ Detect</font><font style="FONT-SIZE:10.5pt; COLOR:#002c40">&#153;</font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">, and finalizing clinical trials and gaining FDA approval for our HP Detect</font><font style="FONT-SIZE:10.5pt; COLOR:#002c40">&#153;</font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40"><i>H. Pylori</i> test and our InFoods&#174; IBS diagnostic-guided therapy product.&#148;</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><b><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">About Biomerica (NASDAQ: </font></b><b><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir">BMRA</font></b><b><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">)</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Biomerica, Inc. (</font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir">www.biomerica.com</font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focus is on Gastrointestinal and inflammatory Diseases where the Company has multiple diagnostic and therapeutic products in development. </font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 8pt; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the efficacy of the Company&#146;s SARS-CoV-2 (COVID-19) tests, the rapidity of testing results, pricing of the Company&#146;s test kits, demand for&nbsp; orders, availability of the Company&#146;s COVID-19 test kits, patent protection on&nbsp; test technology, the Company&#146;s ability to develop and manufacture new products not yet developed or validated, and the efficacy of such undeveloped tests. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation:&nbsp; results of studies testing the efficacy of the Company&#146;s COVID-19 tests; regulatory approvals necessary prior to commercialization of the Company&#146;s COVID-19 tests; availability of the Company&#146;s COVID-19 tests; capacity, resource and other constraints on our suppliers; dependence on our third party supply chain and manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our COVID-19 test; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulations and the Company&#146;s ability to obtain patent protection on any aspects of its&nbsp; test technologies, the Company&#146;s ability to develop and manufacture certain tests it has not yet finalized and has never previously manufactured. &nbsp;Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 8pt; LINE-HEIGHT:22.5pt'><b><font style="FONT-SIZE:11.5pt; FONT-FAMILY:Avenir; TEXT-TRANSFORM:uppercase">Contact Information</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 8pt 0.25in; LINE-HEIGHT:normal'><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir; COLOR:#002c40">Company Spokesperson<br>949-645-2111<br></font><font style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir">www.biomerica.com</font></p></div></body>
<!-- EDGAR Validation Code: 2BD5E8F4 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (" @(" 0(" @(# @(# P8$ P,#
M P<%!00&" <)" @'" @)"@T+"0H,"@@("P\+# T.#@\."0L0$1 .$0T.#@[_
MVP!# 0(# P,# P<$! <."0@)#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.
M#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@[_P  1"  B .L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]^NW]:,\5
M^</[<W[0?Q ^$_C+P#X=^'/B0^';Z[M+B\U1EM(9VD0NB0C$J, ,K-TQG\*T
M/"O@7]MGQ9\*M!\2?\-!Z9I/]JZ;!>I:2Z! 9(?-C#A&(M\9 (!QGG-?31R6
M?U*GBZU6$(SO:[=]';9)GR<L]I_7:F$HTISE3M>R5M5?=M'Z'?PT;<5^,_B#
M]IS]J#X$?M5MX#\?>)-*^(36<\'VBUCL(0MU%* P\MXHXW1RK<!APV/E8=>B
M_:8_:<^-.A_M\ZE\._A?XN?2+"W-E816D>GVT_F74J(Y^:2-FSF55P#C*UZ,
M>%L?.K&G&<7&47)23=K*WE?JNAYLN+<OA1G.4)*4)*+BTKIN_G;IW/UU[TG;
M%?EC\7/VQ/B7)\=;7X*_ ZVAU;Q);7*:3=:_<6RS3WUZOR2>3&<1(H<-EV4@
MX8@*H!/JVF_!#]L;5-(AO/$'[3<6BZHXWR6ECHR311GKMW!8P<=#A<?6N*61
MU,/2C4Q56-/F5XIW;:[V2=EZG?#/Z6)JRIX2E.IRNS:LDGVNVDWZ'WUGGW[T
M?A7X\_$OXT?M:?LO?&32=)\:^-=-^(&BWT7VBR>XL(_)NXT8+(I9425'7(R-
MQ W*<M7?_M+_ +6GC:T^&WP3NOA'J<OAK5O%FDG5KVW%K#<S*LFR.*'#HP/[
MSSAD 9*#Z5TQX9QU2I25.490JWY9)NVBN[Z76SZ'++BK 4Z=5U8RC*E:\6E?
M5V5M6GOW/U'Z+17YB_L3_M'?$[XE?M!^+/!?Q.\3-KDB:/\ :]/2:Q@@:%XI
M@DB_NHUR2) 2&SC9VYK[F^,GQ3T'X-_ #7/'6O2>8EK'Y=E9AL/>7+<10I[L
M1R><*&;H#7D8W*,7@<?]2DE*;M:UVG?:VQ[.!SG"8[+WCHWC!7O>UU8]4[__
M %J.U?@=;_M>?M2:YXUTNVMO'DEBVN7JQZ?%'HMH(_WDQC CW1$LBOE 22<J
M022#7N/QY_:4^.EC_P %!-0^%_PQ\<-I]BEY8Z1:1'3K:02W4B1*[,SQ,PS)
M(P..!MX%?22X0S"%:-*4X7<7*]W9)-7OIY_F?,0XSRZ=&56-.=DU&UE=MWM;
M7R/U^YSZ?A5&\TS3]0BVWUG%<@\$.N:^!_\ A7?_  4"*\?&_P (<C_GR3_Y
M!JCJW_#7'PA^$_CCXB_%+XOZ)K>A:3X=NOL-IIEI%YC7\H$-JS9M$!59)%;&
M[D@ @@FO#CE$)R488BG*3=DES7;>R^'JSW5GDZ?ORP]2,4KMM1226K>DK['V
M]=?#7P%??\?GA+2[G_KI9JW\Q6%-\#_A#<2;IOAQX>F;U;2HC_[+7YL?L\^/
M/VNOVAKGQ0-'^-4'A^UT-8//GO- M9!(TV_:JA8>H$;$Y/<5Z)\6K/\ ;4^#
M7P?U3X@2?'+2_%6BZ84:^@&BVT4JJ\@0,JM!M8!F&1N!P>,XKNJ</SHXOZI+
M$052Z5KRW=K*_+;4JCQEBIX/ZW3A6]E9NZ:V6[MS7/LZ;]G/X%S_ .M^%?AI
MF]?[(B!_]!K(N/V6?V?;O_6?"W15S_SQMS'_ .@D5\#1_MN?$S6_^">OC+69
MI+70_B!INNZ?IUCK5E:)LG6?S96)BD#J'"6\JM@8PZD &M+X;_MB^.O!?[%V
MM?$3XFZO)XZ\3:UKC:9X/TJ6WAM4VV\2M/.S11K^[#3(IZDL%48RS"Y<+9G&
M,KI<RDHJ/5MI.ZTM:SNV[:(Z*/B/*,X^SQ-6*<7)OFDDDM+/6][Z+O<^PKW]
MC']G&\RS?#U;9O6WU6[C_02X_2N-U']@KX%W1;^SX]=T7/\ SZ:R[8_[^!Z\
M+^&.J?MK?M&>&V\:6/Q$T[X9>"IYG2R:+2XQ]HVMM8PJ4:1E5@5W-( 2"!G!
MQ)\7K/\ ;$_9_P#A5-\0/^%YVWC3P_93Q1W\,^DQ"2,2.$0[71MP+,JG:X89
M!QC)'-_8'^T+#2KT_:7M;7?M=1M>^GJ>]2\3N)Z6&^L4ZN)]EO=R;T[V<KVZ
M[';7_P#P3W\.J6;P_P#%;Q/I+_P_:2DX'_? C/ZUYYJW[#?QNTE6;PE\<I+X
MC[BW%S=V7TY1Y*^G_P!DG]H+6/CY\&]8O/$>CV^F^(-$O$M;N:R#""Z#IN5U
M5B2K<,&7)'0@C.T>>?M=?M,>(/ 6MZ'\*/A'.;CXI:M<1&:2WMTN)+)'8"*)
M8V!4RS,1@$'"\XRRD>?#)<54S%X'E2FM]=$K7NVNEM3[*'B]GV'RQ8V>(]I3
M:T4H0DV[VLKJ[=_,^6=4^"W[<G@G=+IWB#Q#KENG_+32O%;3C\(Y75C]-M>;
M:A\?OVN/AW=I#XB\0^)-#=&VA=;T6/:W_ I8CN^H-?07[)_[4'Q:\4?MLI\.
M_BQXF?5K>_M;FU@MI["W@-M>P_/@F.-3G;'*N"2,D=Z_5BZL+&_LI+>\LX;R
MWD&V2.:,,K#W!R#6>:Y5B,JQ*HUI7=DTT[II]KV/K.'_ !>P6<X?VN+RRC5B
MFT_<4975M_B7X(_$G1_V^OCUIQ07TVA:ZB_>^V:849OQB= /RKV3P[_P4CU2
M-TC\4?#*"X7_ ):3:9JK1G\(W0Y_[Z%?7OC_ /8^^!?CRUN)'\(Q>&=4?.+_
M $%A:.I/<HH\MO\ @2&OSP^,7["?Q"\!V5WKG@>Z_P"%@>'X@7D@BA\O4(5'
M)_=@D2X]4.X_W:\!^U6NY^RY7CO"7B6:HXC"K#5):).\$WY2BTOOM?L?:WA+
M]O?X&^()8X=:GU7P;.QV_P#$RT\R1Y_WX2X ]VQ7U5X5\?\ @GQUI!OO"'BG
M3/$5J/OO87B2[/9@I)!]B :_F7=&CE:.13'(C%65A@J1V(J_I.L:OH.NP:EH
MNIW6CZE"V8KJSN6AE3Z,A##\#4*MW/?S3P4RC$0<\MQ$J;Z*5IQ_1KUNS^HG
MKC'2G\8[5^17[.G[<7B.T\8Z5X-^,%T-:T>[E2WMO$)0)<6C,0J^?MPKQY(!
M? 9>I+=OUP#(RAO45U)J2NC^4>)>&,TX5QJPV/BE?6,D[QDNZ?YIZK[C\*?V
MKI[[XP?\%8KCP7HLR-,EU8^&[!Y,[$<XWEL9.%EFDSCG -?:]Q\'_P!M]?#/
MV"U_:%T&.*.'RXHXM)CA^7& NY;;*X' (Z5X)9_L@?M/Z3^U'<_%K2M1\&Q^
M)WUFXU.)[F_EGC268N22K08.W><>A /:O?+KPY_P4*NM/DMU\<> [$NI7SX(
M1O3W&ZV89_"OV+&XJDZ&'H86M1<:<4GSV;YNK5TS^7\#A:RKXC$8NC64ZDFU
MR-I6Z)V:/B'X+ZCI?A'_ (*4P:#\;/!\GCKQXWB@6<FN76LR3&SO-X5+C81M
MF .ULN?E7# 94"N'\&Z]_P )Q_P4@\0?$JXB-U8Z??ZKXM<'D+'9QRW4*_3=
M'$GXBOM7P/\ L/>/] NO&'Q"\4>,=/\ $GQ4NK"\_L1%EE^SQWUS&\9NYYW3
M<Y7S&8*$QNP<G J_^S1^Q;XL^'_C;QU=?%"?2;S2=<\+7&AQQZ3>222;+@J)
M3EHU"G8N >>M>I5SG*81K5HU$Y\D865[-]>5/IJO+0\>GDF<5)4:,J;47-SN
M[72Z<S6[WW[GSS_P3W\.KXA_;FU;Q-J#?:)M&T*>ZC>3YF\^>18MV?78\O/O
M7[<#[U?DOX?_ &0/VDO@3\;;CQ5\%O%VA:Q"4: ?;7,+W,#,&\N:%T*'E5.5
M?((!!%>Y76H?\%!-4TMK&'0_A[X?F==IU"&1F>,_W@&DD7(_W#]*^3S^%'-\
M>L30Q$.1I))RLU;NFK[GV7#U2OD^ >&KX>?.I-MJ-T[]F?)?_!0[Q1_PDG[9
M7AOP9IO^F3:)HR1R11C<WVFY<OLP.Y00''^U6;X=\-KXV_X+"?#GX>V[B\T;
MP#%8Z67 RH&DVXDGW>S72R@^I>OJGX/_ +%.L>'_ (Q3?%GXO>*+?Q[X^BN&
MU"SL87<VWVW[R32S.H9RK8*J$55(!^8 "M+]E7]F'X@?"O\ :/\ &GQ(^)EY
MI&H:MJEF\5J^FW4DS&2><2SN^^--I.U0.N<MT[^S_:^787+7AZ%12=*FXI[7
ME/=I/M9Z^9X+R;,L9F:Q%>FTJLU)K^6$=D[=7V\CY$\$R?\ "F_^"\=WI\S"
MTTV?Q5=6A4G"^3?(S0\] !YT1S_LUT7Q5\2:]^VE_P %!=)^&O@N[DC^&^@S
M./ML8W1B-6 N+]AT);B.('J"OW=[5[/^U1^QY\1?BW^U;+X\\!W6B6]E>:7!
M'>C4;Z6&7[1'N3("Q."OEK&,YSD'BOI']EG]GFW^ GP/N+34FMK[QUJ[B;6[
M^WR4&W(C@C9@#L0$G) RS,>F (Q.;9;#"T\PC-2Q*IJ"7\KUO)^E]#?#9/F<
M\55RZ47'#.;FWW6EHKUZGYYWNAZ#JG_!;WPGX+T.&.Q\'>![BUM;5"1L@@TV
MV^U2ECW)E27)/)8DGDFO%?A?X;\7?M!?\%"]2O/"OB ^%=?OM3O-?CU<Q&0V
M.V0R(P4$'(9XT'/!(]*^T/#?[)'QMTWXS_&CQ]J-SX=DUWQ/HVJV^C>5JDS?
M9[F_E ,C,81M"0O-@C)W8&,<CB_AC^R3^UG\'?&=[X@\ ^(O!NDZM=69LYIY
M;AKC,6]7*@26S 99%.1SQ7L4\TP4:,_9UH<ZIQ@G)Z-ZN3>CONKZ:M'B3RK'
M2K0]I0GR.I*;45JEHHI:KL[;6N>[-^S;^U7Y1'_#5E[R.UI*/UWUY;^U7;>,
M_A3_ ,$S]&^'WCKQ]<?$#Q9XD\4^9=:C<.QS;1#S-B!B3M5D@X_O,3WKT[_A
M%_\ @HAG_DHO@K_P'B_^0ZX'XU?LR_M0?&CPG\.H_%7B+PQJVM:+8W7]H7+W
M;6Z-//<,0$2.W"[5ACMQNP"6W>@)^;P=6,<=2GBZ]%PC*[Y4D[I-K516E_,^
MHQE&4\#5A@\/54Y*RYVVK-I/1R?0\Y_97\*_M6>'_P!FN3Q%\'K'PDOAKQ#>
MO<!]:8_:IFB)@..@"AHVP">['O7F_P ?/B5\>KKXBV?PS_:4U2]\+^%Y!'=W
M-EX:L+9UN8MYVR@^8!* RMA6DP&'W0P%?L=\(_!+?#G]F;P/X'F,;76CZ/!;
M730G,;SA!YK*2 2#(6() )S7QS^U_P#LO_$OXZ?&OPSKW@NXT2'3;#1OLLW]
MI7DD,GF&5W. L3@KAEYSUSQ6F#SW"8G.YSQ$*<8MR:G;WE;X7=W5]NA&-R#&
M8;(H0P\YN223A?W7?=673YGQC^U!I/P[^'_[/_P7^'_PNN)K[0=4LI/%5[?W
M;?Z1J#7")%!+(, +A$E4(  !QC.XGQ7XO0RZ3H7PE\$?,JZ7X+MKJ2)N,7&H
M2/>N3[[)H4_X /2OMCXJ?L1_&;QQ\3?#KZ;?>'(/#.C>'-,T.R\_49A*L5M;
M(DAVB$CF4S,.>01G!)KV3]I3]B63XJ>)]/\ %?P^URTT'7K;3(;"XT_4486U
MRD*[8F61%9D8+A2-K @+]W!S]%A<\RW#1P].I6YK\TI2W:D]KV\FUV/F,5D.
M:8J5>K3H\MN1**T32WM?S29]L?#SPQ:^"_@;X0\)V:*EOI.D6]HNW^(I&%+?
M4D$D]R37*_%[Q]\(/!O@^SLOC!J6E6VAZM*4@L]6LC=1W31[6/[O8V=IVG)&
M 2.^*^2_#>F?\% _"GA.TT!9/!/B6WM(EA@OM3FWS[5&%RRE"Q  ^9E+'N2:
MY+5OV/\ X[?''XL6/B?]H+XE:9#86R^7%IV@QM(T,6<M'$"BQQECU<^8QP,[
ML"OSF&7818MU<7BH\EVVX-N3ZJRL[/U/TR>98R6#5'"86?/9*TTE%+9WUU5C
MZ!\:?'+X-_!K]BB?XD?#73]%%EKCR1^';/2].%E'JEVI:,NR!$)1"A+.1]U<
M Y*Y_./X,VWQZTOXU3?'@_!'5/BGK>LH]WIVJ7\;K$CRYW3Q@=<I\BG[H4_*
M.A'U)KG['GQ"^(?[4GA1O&$NB:%\$/#$:V.CZ!INHRS3QV,7*H<QJ/,F9099
M-V[DX+;5K]*K.SMM/TJWL;.WCM;.WB6*&") J1HH"JJJ.     .@KT/[1P.4
MX9TZ"56=6_,VWI'I&Z:UMO;3Y'F1RS'YQBE4Q#=&%*R@DEK+K*S3TOMH?SJ^
M*M<\;?#W]OJW^(7B3P9<> O$)U^/Q$=%D!&%:<NX7/)1R)!^)':OZ)]-U"TU
M7PW8:II\RW-E>6Z3V\J]'1U#*P^H(-?"7[8G[+?B[XZ>-O!WB3P)-I5OJEA9
M2V>I?VG<O#YD6X/#M*QOG:S39!Q]X5].? KPWXN\$_LH>"_"'CR:RD\1:-9?
M899;&Y:6)XHV*PD,RJ<B(1@Y'4&IS['83,\NPV(@TJD;Q<4]4NF^MM/Q->'L
M!C,KS/$X>:;IR:DI-:-]=M+ZZ^A[!^%-QN^7''>N7\3>-O"/@O1&U'Q9XDT[
MP_8C_EM?WB0J?8;B,GV&37Q[XZ_;,M[Y+K1/@)X*UGXI>(#F--0MM,G^P6[=
M,G"[Y,'L JG^]7YZ]-S]JRW(\SS6=L-3;CUD](KS<G9+[SXS_;X\*>%O#G[7
M>GWWA]8;74M9TO[9K%K  H\WS&592HZ,X7GU*DGDDGX<^;VK[KA_9(_:6^,_
MQ(O/&7Q"^S>'[W4Y?,N;S6;M6DVX  2&'=M"J H0[<  <5]=_#3]@/X8>$[B
MWU#QM>7/Q!U./YO)G7[-9!O^N2DEOHSE3W%<KA*<KVL?VU@N.^'.#\@H8#$X
MKZS6I12?L_>U[*6UELKN]EL?F]^S]^SWXN^-WQ.LH[6QFLO!EM<*VL:U*A6*
M- 06CC)X>1AP ,[<@M@5_0DB[8E7T %9^EZ3IFB:%;Z7H^GV^F:;;H(X+:UB
M6*.-1T"JH  ]@*U,?[-=$8J*L?RCQIQEB^,<?&M5@H4Z::A%:M7M=M]6[+R5
MAU%%%4?F84444 %%%% !1110 4444 %%%%+H 4444P"BBBD@(O\ EJGTJ0_=
MHHIC$;K2C[M%% A.ZTUOXOI1168T4Y&8-PQ'XU\#?ME^+/%/A[PO = \2ZKH
M9888Z?J$L&[Z[&%%%;1W/HLH_P!]B<I^RMX5\+^+=#37/%7AO2_$VMD[CJ&K
M:?%=7&?7S)%+9_&OTBT^SL[72HX;6UAMHE3Y4BB"JOT %%%$/A/N^,/XJ^7Y
-&E1114GY"%%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
